Syntekabio and Enamine team up for AI-driven drug development

Syntekabio, an AI drug discovery firm, has entered into a partnership with Ukraine-based global compound supplier Enamine. This collaboration, formalized under a Memorandum of Understanding (MOU), aims to enhance the development of synthetic drugs through the integration of AI and extensive compound libraries.

The partnership leverages Enamine’s comprehensive synthetic compound library to bolster Syntekabio’s drug candidate discovery processes via its AI platform, DeepMatcher. Both companies are set to operate from the AI Bio Supercomputer Center (ABS Center) in Daejeon, South Korea. Their combined efforts focus on creating optimized lead compounds, merging Syntekabio’s AI proficiency with Enamine’s expertise in chemical synthesis and preclinical biology services.

A significant aspect of this alliance involves joint marketing strategies intended to expedite their growth in the global AI-driven drug discovery market. Enamine is actively expanding its global footprint, with branches established in the US, Germany, and Poland. The company’s service offerings are extensive, encompassing in vitro efficacy verification, binding assays, and ADMET screening, which refers to the absorption, distribution, metabolism, excretion, and toxicity of compounds.

Enamine plans to utilize its extensive knowledge in chemical synthesis and preclinical biology to support Syntekabio in optimizing therapeutics and extracting lead compounds, using Syntekabio’s AI-based molecular design technology. This synergy is expected to significantly advance the field of synthetic drug development.

Additionally, Syntekabio is engaged in bio-drug research through its NEO-ARS and Ab-ARS services. NEO-ARS provides personal and shared neoantigen prediction services, while Ab-ARS is focused on the discovery and optimization of new antibodies.

Dr. Iaroslava Kos, Enamine’s business development director, expressed enthusiasm about the partnership, stating, “We are excited to collaborate with Syntekabio to integrate our extensive compound library with their advanced AI platform. This partnership aims to accelerate the discovery of optimized lead compounds, enhancing the efficiency and effectiveness of drug development. By combining our strengths, we look forward to making significant advancements in the field of synthetic drug development.”

The collaboration between Syntekabio and Enamine represents a strategic melding of AI technology and chemical synthesis expertise, poised to drive significant progress in drug discovery and development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!